<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS200047</article-id><article-id pub-id-type="doi">10.1101/2024.11.11.622946</article-id><article-id pub-id-type="archive">PPR938182</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antimicrobial susceptibility testing of Clostridioides difficile: a dual-site study of three different media and three therapeutic antimicrobials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Freeman</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib><contrib contrib-type="author"><name><surname>Sanders</surname><given-names>Ingrid M.J.G.</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Harmanus</surname><given-names>Céline</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Emma V.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Berry</surname><given-names>Andrea M</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Smits</surname><given-names>Wiep Klaas</given-names></name><xref ref-type="aff" rid="A2">b</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib><on-behalf-of>on behalf of the European Society of Clinical Microbiology and Infectious Diseases Study Group on <italic>Clostridioides difficile (ESGCD).</italic></on-behalf-of></contrib-group><aff id="A1"><label>a</label>Leeds Teaching Hospitals National Health Service (NHS) Trust &amp; <institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mrxd33</institution-id><institution>University of Leeds</institution></institution-wrap>, <city>Leeds</city><postal-code>LS1 3EX</postal-code>, <country country="GB">UK</country></aff><aff id="A2"><label>b</label>Experimental Bacteriology Research Group, Leiden University Center for Infectious Diseases (LUCID), <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Leiden University Medical Center</institution></institution-wrap>, <city>Leiden</city>, The <country country="NL">Netherlands</country></aff><author-notes><corresp id="CR1">
<label>#</label>Address correspondence to Jane Freeman <email>jane.freeman4@nhs.net</email> or Wiep Klaas Smits <email>w.k.smits@lumc.nl</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>13</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>11</day><month>11</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Objectives</title><p id="P1">Increasing resistance to antimicrobials used for the treatment of <italic>Clostridioides difficile</italic> infections necessitates reproducible antimicrobial susceptibility testing. Current guidelines take a one-size-fits-all approach and/or offer limited guidance. We investigated how the choice of medium affects measured MIC values across two sites.</p></sec><sec id="S2"><title>Methods</title><p id="P2">We determined MIC values for the antimicrobials fidaxomicin, metronidazole and vancomycin for a representative collection of European <italic>C. difficile</italic> strains (n=235) using agar dilution on three different media: Brucella Blood Agar (BBA), Fastidious Anaerobe Agar supplemented with horseblood (FAA-HB) and Wilkins-Chalgren (WC) agar. The study was conducted at two sites to compare reproducibility. Useability (ease of preparation of the media as well as read-out of the assay) was assessed through a survey.</p></sec><sec id="S3"><title>Results</title><p id="P3">We found that all media result in highly consistent aggregated MIC data for all antibiotics, with MIC<sub>50</sub> and MIC<sub>90</sub> within 2-fold of each other across sites. For fidaxomin, MIC values on WC were lower than on the other media. Metronidazole showed the lowest MIC on BBA, and the highest on WC. For vancomycin, there was little difference between media. Though absolute values for individual isolates differed between sites, identified resistant isolates were similar. Results obtained on FAA-HB were most consistent between sites and results obtained on WC showed the most divergence. FAA-HB was positively evaluated in the usability survey.</p></sec><sec id="S4"><title>Conclusionss</title><p id="P4">This study shows medium-dependent differences in <italic>C. difficile</italic> MICs for at least two antimicrobials across two sites. We suggest the use of FAA-HB to align with general EUCAST recommendations for susceptibility testing of anaerobic bacteria and deposited reference strains for standard susceptibility testing of <italic>C. difficile</italic> to increase interlaboratory reproducibility.</p></sec></abstract><kwd-group><kwd><italic>Clostridioides difficile</italic></kwd><kwd>antimicrobial susceptibility test</kwd><kwd>metronidazole</kwd><kwd>fidaxomicin</kwd><kwd>vancomycin</kwd><kwd>agar dilution</kwd></kwd-group></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P5"><italic>Clostridioides difficile</italic> is a clinically important bacterium that can cause potentially fatal gastro-intestinal disease [<xref ref-type="bibr" rid="R1">1</xref>]. The disease is associated with a high burden on healthcare systems, society and the economy [<xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R5">5</xref>]. At present, three antimicrobial treatments are indicated by international guidelines: fidaxomicin and vancomycin are first line treatments [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R7">7</xref>] except the UK, where only vancomycin is recommended as first-line)[<xref ref-type="bibr" rid="R8">8</xref>]. Metronidazole is no longer recommended due to clinical inefficacy unless first line therapeutics are not available or contra-indicated [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. However, despite clinical inferiority metronidazole is still widely used [<xref ref-type="bibr" rid="R8">8</xref>].</p><p id="P6">Reduced susceptibility or resistance of <italic>C. difficile</italic> has been reported for all three antimicrobials [<xref ref-type="bibr" rid="R9">9</xref>]. However, reported rates of resistance, particularly for metronidazole, vary widely and the reasons for this are poorly understood. Though geography and lineage of <italic>C. difficile</italic> might contribute to different rates of resistance, it may also attributable to differences in testing methodology [<xref ref-type="bibr" rid="R10">10</xref>]. Current EUCAST and CLSI guidelines both advocate the use of Brucella Blood Agar for the determination of antibiotic MICs for all anaerobes, including <italic>C. difficile</italic>, but differ in the breakpoints defined [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>]</p><p id="P7">Recent studies on metronidazole resistance in <italic>C. difficile</italic> underscore the issues outlined above. Whereas most studies report limited metronidazole resistance [<xref ref-type="bibr" rid="R10">10</xref>], rates up to 44.6% have been reported in Israel [<xref ref-type="bibr" rid="R11">11</xref>]. Metronidazole resistance can be plasmid-mediated [<xref ref-type="bibr" rid="R12">12</xref>], but a subset of isolates demonstrates plasmid-independent resistance [<xref ref-type="bibr" rid="R13">13</xref>]. Importantly, the latter group demonstrates strong medium-dependence [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>]. This is suggested to be due to a mutation in the promoter of gene <italic>nimB</italic>, resulting in constitutive transcription [<xref ref-type="bibr" rid="R18">18</xref>]. Finally, it has been suggested that reduced susceptibility (MIC≥1 mg/L when tested on non-consensus medium) is associated with treatment failure [<xref ref-type="bibr" rid="R15">15</xref>]. Vancomycin and fidaxomicin achieve gut concentrations several orders of magnitude above the MIC of <italic>C. difficile</italic> isolates classified as resistant to these drugs, and therefore the clinical significance of resistance against these drugs is not yet clear. Data is lacking on whether medium composition affects vancomycin and fidaxomicin susceptibility.</p><p id="P8">Together these data clearly show the importance or routine screening of <italic>C. difficile</italic> using standardised conditions that might benefit from a re-evaluation of resistance breakpoints.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><p id="P9">As minor differences were inevitable between sites, the catalog numbers of individual chemicals is provided as a <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 1</xref>. An standard operating procedure (SOP) is available as <xref ref-type="supplementary-material" rid="SD1">Supplemental Text</xref>.</p><sec id="S7"><title>Strain selection</title><p id="P10">We selected n=250 isolates that were collected during the COMBACTE-CDI (2018) and ClosER studies (2011-2016) [<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R17">17</xref>]. The isolates were selected to comprise at least 10 isolates of the top ten most prevalent European PCR ribotypes, as well as recently emerging ribotypes or ribotypes associated with multi-drug resistance (resistance to&gt;3 antimicrobial classes) (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table 2</xref>). We included isolates that were previously identified as showing reduced susceptibility towards metronidazole (n=39), vancomycin (n=31) or fidaxomicin (n=1) [<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R17">17</xref>].</p><p id="P11">To reduce differences arising from repeated sub-culturing, <italic>C. difficile</italic> isolates were subcultured on cycloserine-cefoxitin egg yolk agar (E&amp;O laboratories, Bonnybridge, Scotland, UK) for 48h in Leeds. Duplicate sets of glycerol stocks were prepared by resuspending the growth in glycerol broths, dividing into two aliquots and freezing at -80°C; one aliquot was sent on dry ice to Leiden. Control strains (<italic>C. difficile</italic> ATCC 700057, <italic>C. difficile</italic> E4 [<xref ref-type="bibr" rid="R18">18</xref>], <italic>Bacteroides fragilis</italic> ATCC 25285 and <italic>Enterococcus faecalis</italic> ATCC 29212) were similarly shared between both sites.</p></sec><sec id="S8"><title>Antimicrobial susceptibility testing</title><p id="P12"><italic>C. difficile</italic> isolates were removed from -80°C storage and subcultured anaerobically to ensure purity, prior to inoculation of pre-reduced Schaedler’s anaerobic broth for 24h [<xref ref-type="bibr" rid="R13">13</xref>]. Isolates were transferred to pre-reduced sterile saline and adjusted to McFarland standard 1.0. Non-antibiotic containing plates were incubated aerobically and anaerobically.</p><p id="P13">Antibiotic-containing agar plates were prepared by mixing 2mL dilution of the antimicrobial with 18 mL molten agar and distributing into petri dishes. Blood, haemin and Vitamin K were added after autoclaving and prior to distribution into petri dishes (<xref ref-type="supplementary-material" rid="SD1">Supplemental Text</xref>). Fidaxomicin was dissolved in 100% DMSO as a solvent, and further diluted into 10% DMSO as a diluent.</p><p id="P14">Metronidazole was dissolved in 100% DMSO as a solvent, and further diluted into water as a diluent. Vancomycin was dissolved in water as a solvent, and further diluted into water as a diluent. The final concentrations of the antimicrobials in the agar dilution experiments were 0.015-16 mg/L for fidaxomicin, 0.125-32 mg/L for metronidazole and 0.125-32 mg/L for vancomycin.</p><p id="P15">Saline suspensions of <italic>C. difficile</italic> isolates were inoculated onto agar plates using a multipoint inoculator and incubated anaerobically for 48h. The minimum inhibitor concentration is defined as the lowest dilution at which growth is completely inhibited or where only a single colony remains.</p></sec><sec id="S9"><title>Analysis and visualisation</title><p id="P16">Plates were read by two technicians and results were logged only when control strains demonstrated MIC values within a predefined range (<xref ref-type="table" rid="T1">Table 1</xref>). For fidaxomicin no breakpoints were defined at the time of testing (2019). We therefore defined breakpoints for this study as ≤1 mg/L: susceptible; &gt;1 mg/L: resistant, in line with those used in the CLosER study [<xref ref-type="bibr" rid="R16">16</xref>]. For metronidazole and vancomycin, EUCAST breakpoints at the time of testing were used (≤2 mg/L: susceptible, &gt;2 mg/L: resistant. MIC<sub>50</sub> and MIC<sub>90</sub> were determined on the basis of ranked MIC values.</p><p id="P17">Data were collected in Microsoft Excel and converted into a tidy format (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table 2</xref>). Graphs were generated in SuperPlotsOfData [<xref ref-type="bibr" rid="R19">19</xref>] and Eulerr [<xref ref-type="bibr" rid="R20">20</xref>], and further compiled in Adobe Illustrator 2022 (26.3.1).</p></sec></sec><sec id="S10" sec-type="results"><title>Results</title><sec id="S11"><title>Agar dilution provides highly similar overall susceptibility data between sites</title><p id="P18">Of the n=250 strains that were initially selected, some could not be revived from the original stocks. As a result, n=235 isolates were shared between laboratories in Leeds and Leiden. During the experiments in the Leeds laboratory, 3 additional isolates we judged not to contain <italic>C. difficile</italic> upon subculture and were excluded from the subsequent analysis.</p><p id="P19">MIC<sub>50</sub> and MIC<sub>90</sub> values were generally within 2-fold of each other between sites; only for the vancomycin MIC<sub>50</sub>, a 4-fold difference was observed on BBA medium. When differences were observed, MIC values were higher at the LUMC site in comparison to the Leeds site. This suggests that subtle differences in experimental procedures may lead to a systematic difference in MIC values measured.</p><p id="P20">MIC ranges show a similar trend; when differences are observed, these are mostly at the lower end of the MIC range and maximum MIC values are within 2-fold of each other. Any differences are therefore unlikely to affect the qualification of strains as resistant.</p></sec><sec id="S12"><title>Fidaxomicin and metronidazole show medium-dependent differences in antimicrobial susceptibility</title><p id="P21">Next, we compared the distribution in MIC values observed for each combination of medium and antibiotic. Overall, we observed a strikingly similar pattern for values determined in Leeds (<xref ref-type="fig" rid="F1">Figure 1A</xref>) and Leiden (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p><p id="P22">As also noted above, mean values determined at Leiden appear to be slightly higher than those determined in Leeds. However, within sites, the different antimicrobial-medium combinations show similar trends. For fidaxomicin, we find that mean MICs are similar for FDX and MTZ, but are markedly lower for WC medium. This suggest that the use of WC in agar dilution experiments may lead to a systematic underestimation of potential reduced susceptible isolates, compared to other media. An opposite pattern is observed for metronidazole: mean MIC values progressively increase from BBA, through FAA-HB to WC medium. Thus, for both fidaxomicin and metronidazole there is a strong medium-dependent effect on susceptibility. For vancomycin, results indicate a lesser medium-dependence with mean values being similar for all media in the Leeds dataset, and only WC resulting in slightly lower mean MIC values in the Leiden dataset.</p></sec><sec id="S13"><title>Interlaboratory differences differ per medium used</title><p id="P23">Though aggregated data shows highly similar trends (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F1">Figure 1</xref>), this analysis could potentially mask differences between the MIC values for individual isolates obtained in the two laboratories. In order to assess this, we calculated the ratio of the MIC values for each isolate; if data were 100% congruent, this should result in a ratio of 1 (the same MIC value). We find that the mean value indeed approaches this (<xref ref-type="fig" rid="F2">Figure 2A</xref>), in particular for FDX on all media.</p><p id="P24">A high reproducibility should result in a tight clustering of datapoints. We note that data obtained on FAA-HB medium shows a narrower distribution of ratios, compared to BAA and WC (<xref ref-type="fig" rid="F1">Figure 1A</xref>).</p><p id="P25">Next, we assessed how medium-antimicrobial combinations affect the identification of resistant isolates, which we deem to be the clinically most relevant outcome parameter. We identified all isolates with an MIC &gt; 1 mg/L (FDX) or MIC&gt;2 mg/L (MTZ or VAN) (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table 2</xref>) on one or more medium-antimicrobial combinations. As expected, the number of isolates identified in this way was higher for the Leiden site than the Leeds site, consistent with the higher mean MIC values.</p><p id="P26">However, in general, those isolates identified in Leeds were also identified in Leiden (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Notably, however, identifications of vancomycin resistant isolates and/or identifications on WC medium showed a significant laboratory-specific effect. The most consistent results were observed for FAA-HB medium, where all isolates identified as resistant in Leeds were also identified in Leiden.</p></sec><sec id="S14"><title>Distinct media offer easier handling or read-out</title><p id="P27">We considered several aspects that might contribute to experimental variability in our data. In particular steps necessary to prepare media, as well as the ability to clearly read the MIC data stemming from the agar dilution data appeared to be important sources of variation to us. We therefore queried the teams that performed the experiments about these aspects. Four members of staff were surveyed, with three giving feedback using Likert scales on ease of preparation, readability and detection of contamination (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table S3</xref>). The currently CLSI-recommended Brucella Blood Agar consistently scored least well on all survey questions and was the least preferred option among staff performing the procedure.</p></sec></sec><sec id="S15" sec-type="discussion"><title>Discussion</title><p id="P28">Here, we determined how the choice of medium affects antimicrobial susceptibility testing for <italic>C. difficile</italic> for therapeutic antimicrobials fidaxomicin, metronidazole and vancomycin. We find that agar dilution offers a reliable assessment of susceptibility with minor systematic differences between sites using a harmonized protocol. There were mechanical differences in agar preparation method between the two sites (Leeds used an automated agar preparation, while Leiden used a hand-poured agar technique) which may account for such minor differences. Nonetheless, we found clear evidence for medium-dependent susceptibility for fidaxomicin and metronidazole, and show that determining susceptibility on FAA-HB medium shows the highest inter-laboratory reproducibility. FAA-HB also scored highly for ease of use, ease of reading MICs and detection of contamination among staff performing the procedure, in contrast to BBA, which was consistently the lowest scoring medium.</p><p id="P29">Medium dependent resistance in <italic>C. difficile</italic> has so far only been described for metronidazole [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>], and medium-dependent effects on fidaxomicin susceptibility have to the best of our knowledge not been documented before. Though the use of WC could clearly result in lower MIC values for fidaxomicin (and possibly vancomycin), it should be noted that this does not affect the identification of highly resistant strains [<xref ref-type="bibr" rid="R21">21</xref>]. FDX-reduced susceptible strains have rarely been identified but the inclusion of the only FDX-resistant <italic>C. difficile</italic> isolate so far identified in large scale surveillance studies [<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R24">24</xref>] gives confidence that FDX resistance would be detected on the recommended FAA-HB medium . For metronidazole, heme in the medium appears to be a key determinant for resistance, and it should be noted that when using any fresh blood based medium for determining metronidazole MICs in <italic>C. difficile,</italic> blood should be fresh, to avoid degradation of haemin [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>].</p><p id="P30">The mechanisms behind metronidazole resistance are only recently being elucidated: plasmid-mediated and <italic>nim</italic> gene expression. Importantly, the use of FAA-HB as recommended on the basis of this study can detect both types of metronidazole resistance. The reason for increased susceptibility for fidaxomicin (and potentially vancomycin) on WC medium is at present unknown, but may be influenced by the more defined and minimal nature of WC, compared to the blood-supplemented media (FAA-HB and BBA). This may marginally increase growth and accentuate differences at the lower end of concentration ranges seen for fidaxomicin.</p><p id="P31">The strengths of the present study include the well-controlled setup and the inclusion of a large number of representative <italic>C. difficile</italic> isolates. Our data is limited by the fact that we did not perform an in-depth analysis of potentially discrepant results, and did not perform repeat testing of the same set of isolates.</p><p id="P32">Our study suggests that the use of BBA medium for agar dilution as recommended in some current susceptibility testing guidelines (e.g. CLSI) might lead to an underestimation of in particular metronidazole resistance and could contribute to inter-laboratory variation in reported MIC values. Our data support the use of FAA-HB medium for susceptibility testing in <italic>C. difficile</italic>, since it offers a good balance of usability, reproducibility and sensitivity. Notably, this is in line with studies of disk susceptibility in other anaerobes, including <italic>Bacteroides</italic>/<italic>Phocaeicola</italic>/<italic>Parabacteroides</italic>, <italic>Prevotella</italic>, <italic>Fusobacterium</italic>, <italic>Clostridium</italic> and <italic>Cutibacterium</italic> and now part of EUCAST recommendations [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>].</p><p id="P33">The increasing number of reports of <italic>C. difficile</italic> with reduced susceptibility or resistance to the antibiotics tested here [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R24">24</xref>–<xref ref-type="bibr" rid="R26">26</xref>] warrants a systematic surveillance of drug resistance for this organism and a re-evaluation of breakpoints. At present, prevalence of resistant isolates varies strongly between reports and is subject of dispute [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>]. A consensus method for susceptibility testing can contribute to inter-laboratory reproducibility. These data support the adoption of FAA-HB as the optimal medium for determining <italic>C. difficile</italic> susceptibility to relevant agents for treatment. They also support the current EUCAST breakpoints for metronidazole, vancomycin and fidaxomicin (≤ 2mg/L: susceptible, &gt;2 mg/L: resistant; v14.0, 01-Jan-2024)[<xref ref-type="bibr" rid="R28">28</xref>], while noting that the panel were selected to include isolates previously showing reduced susceptibility to metronidazole and fidaxomicin. The panel included only one <italic>C. difficile</italic> isolate known to harbour fidaxomicin resistance (16 mg/L), with the remaining isolates demonstrating susceptibility 0.004 and 4mg/L. More than 99% of <italic>C. difficile</italic> isolates were susceptible at &lt;1mg/L fidaxomicin, and &gt;95% at &lt;0.5mg/L on FAA-HB (aggregated data from both sites). To further assist laboratories undertaking susceptibility testing of <italic>C. difficile</italic> isolates, we have deposited isolates that were identified as resistant against FDX, MTZ and VAN in both laboratories at the NCTC for use as reference strains by other laboratories (<xref ref-type="table" rid="T3">Table 3</xref>) in addition to the guideline-recommended <italic>C. difficile</italic> ATCC 70057. Use of these strains in future work will facilitate interlaboratory comparisons of absolute MIC values.</p><p id="P34">The results from the present study have been communicated to EUCAST and will be recommended for determination of <italic>C. difficile</italic> MICs by agar dilutions in the next revision of their guidance.</p><p id="P35">Beyond the relevance for the epidemiological monitoring of the emergence of strains resistant to treatment antimicrobials, the approach proposed here may help to effectively guide healthcare professionals in treating CDI patients.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Information</label><media xlink:href="EMS200047-supplement-Supplemental_Information.zip" mimetype="application" mime-subtype="zip" id="d14aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplemental Information</label><media xlink:href="EMS200047-supplement-Supplemental_Information.pdf" mimetype="application" mime-subtype="pdf" id="d14aAcEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S16"><title>Acknowledgements</title><p>The authors wish to acknowledge members of the Leeds and Leiden research groups for discussions.</p><sec id="S17"><title>Funding</title><p>This work was funded through the ESCMID Study Group grant “Dual-site comparative evaluation of three different media for determining minimum inhibitory concentrations of treatment antimicrobials to <italic>Clostridioides difficile</italic>, to inform susceptibility testing guidelines (2021)”.</p><p>JF is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.</p></sec></ack><fn-group><title>Transparency declaration</title><fn id="FN1"><p id="P36"><bold>Access to data</bold></p><p id="P37">All data is contained in the manuscript and the provided Supplemental Materials.</p></fn><fn id="FN2" fn-type="conflict"><p id="P38"><bold>Conflict of interest</bold></p><p id="P39">JF has received research funding from Pfizer and Crestone, and speaking honoraria and sponsorship to attend meetings from Tillotts.</p><p id="P40">WKS has performed research for Cubist Pharmaceuticals, and holds a public-private partnership grant with Acurx Pharmaceuticals.</p><p id="P41">All other authors: none to declare.</p></fn><fn id="FN3" fn-type="con"><p id="P42"><bold>Contribution</bold></p><p id="P43">JF: writing, supervision, writing-original draft; CH: investigation; IMJGS: investigation; EVC: investigation; AMB investigation; WKS: formal analysis, data curation, writing-original draft, visualization, supervision. All authors reviewed and edited the manuscript, and approved the final version.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>WK</given-names></name><etal/></person-group><article-title>Clostridium difficile infection</article-title><source>Nat Rev Dis Primers</source><year>2016</year><volume>2</volume><elocation-id>16020</elocation-id><pub-id pub-id-type="pmcid">PMC5453186</pub-id><pub-id pub-id-type="pmid">27158839</pub-id><pub-id pub-id-type="doi">10.1038/nrdp.2016.20</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingen-Heimann</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)</article-title><source>Clin Microbiol Infect</source><year>2023</year><volume>29</volume><issue>5</issue><elocation-id>651 e1-651 e8</elocation-id><pub-id pub-id-type="pmid">36586512</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guh</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>14</issue><fpage>1320</fpage><lpage>1330</lpage><pub-id pub-id-type="pmcid">PMC7861882</pub-id><pub-id pub-id-type="pmid">32242357</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1910215</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reigadas Ramirez</surname><given-names>E</given-names></name><name><surname>Bouza</surname><given-names>ES</given-names></name></person-group><article-title>Economic Burden of Clostridium difficile Infection in European Countries</article-title><source>Adv Exp Med Biol</source><year>2018</year><volume>1050</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">29383660</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessa</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Burden of Clostridium difficile infection in the United States</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>24</issue><fpage>2369</fpage><lpage>70</lpage><pub-id pub-id-type="pmcid">PMC10880113</pub-id><pub-id pub-id-type="pmid">26061850</pub-id><pub-id pub-id-type="doi">10.1056/NEJMc1505190</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Prehn</surname><given-names>J</given-names></name><etal/></person-group><article-title>European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults</article-title><source>Clin Microbiol Infect</source><year>2021</year><volume>27</volume><supplement>Suppl 2</supplement><fpage>S1</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">34678515</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults</article-title><source>Clin Infect Dis</source><year>2021</year><volume>73</volume><issue>5</issue><fpage>755</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">34164674</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><issue>11</issue><fpage>1944</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">32343766</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickramage</surname><given-names>I</given-names></name><name><surname>Spigaglia</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Mechanisms of antibiotic resistance of Clostridioides difficile</article-title><source>J Antimicrob Chemother</source><year>2021</year><volume>76</volume><issue>12</issue><fpage>3077</fpage><lpage>3090</lpage><pub-id pub-id-type="pmcid">PMC8598299</pub-id><pub-id pub-id-type="pmid">34297842</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkab231</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sholeh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis</article-title><source>Antimicrob Resist Infect Control</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>158</fpage><pub-id pub-id-type="pmcid">PMC7517813</pub-id><pub-id pub-id-type="pmid">32977835</pub-id><pub-id pub-id-type="doi">10.1186/s13756-020-00815-5</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>A</given-names></name><etal/></person-group><article-title>A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole</article-title><source>Diagn Microbiol Infect Dis</source><year>2015</year><volume>83</volume><issue>1</issue><fpage>21</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">26116225</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boekhoud</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Plasmid-mediated metronidazole resistance in Clostridioides difficile</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>598</fpage><pub-id pub-id-type="pmcid">PMC6992631</pub-id><pub-id pub-id-type="pmid">32001686</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-14382-1</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boekhoud</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile</article-title><source>J Antimicrob Chemother</source><year>2021</year><volume>76</volume><issue>7</issue><fpage>1731</fpage><lpage>1740</lpage><pub-id pub-id-type="pmcid">PMC8212768</pub-id><pub-id pub-id-type="pmid">33876817</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkab097</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests</article-title><source>J Clin Microbiol</source><year>2021</year><volume>59</volume><issue>9</issue><elocation-id>e0058521</elocation-id><pub-id pub-id-type="pmcid">PMC8373004</pub-id><pub-id pub-id-type="pmid">34132582</pub-id><pub-id pub-id-type="doi">10.1128/JCM.00585-21</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales-Luna</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection</article-title><source>Open Forum Infect Dis</source><year>2021</year><volume>8</volume><issue>8</issue><elocation-id>ofab365</elocation-id><pub-id pub-id-type="pmcid">PMC8351808</pub-id><pub-id pub-id-type="pmid">34381844</pub-id><pub-id pub-id-type="doi">10.1093/ofid/ofab365</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2020</year><volume>39</volume><issue>1</issue><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="pmcid">PMC6962284</pub-id><pub-id pub-id-type="pmid">31811507</pub-id><pub-id pub-id-type="doi">10.1007/s10096-019-03708-7</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viprey</surname><given-names>VF</given-names></name><etal/></person-group><article-title>A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018</article-title><source>Euro Surveill</source><year>2022</year><volume>27</volume><issue>26</issue><pub-id pub-id-type="pmcid">PMC9248264</pub-id><pub-id pub-id-type="pmid">35775426</pub-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.26.2100704</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etifa</surname><given-names>P</given-names></name><etal/></person-group><article-title>Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model</article-title><source>Antibiotics (Basel)</source><year>2023</year><volume>12</volume><issue>3</issue><pub-id pub-id-type="pmcid">PMC10044524</pub-id><pub-id pub-id-type="pmid">36978302</pub-id><pub-id pub-id-type="doi">10.3390/antibiotics12030435</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name></person-group><article-title>SuperPlotsOfData-a web app for the transparent display and quantitative comparison of continuous data from different conditions</article-title><source>Mol Biol Cell</source><year>2021</year><volume>32</volume><issue>6</issue><fpage>470</fpage><lpage>474</lpage><pub-id pub-id-type="pmcid">PMC8101441</pub-id><pub-id pub-id-type="pmid">33476183</pub-id><pub-id pub-id-type="doi">10.1091/mbc.E20-09-0583</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>J</given-names></name></person-group><source>eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses R package version 6.1.1 2021</source><date-in-citation>cited 2023</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=eulerr">https://CRAN.R-project.org/package=eulerr</ext-link></comment></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchandin</surname><given-names>H</given-names></name><etal/></person-group><article-title>In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile</article-title><source>J Antimicrob Chemother</source><year>2023</year><volume>78</volume><issue>8</issue><fpage>1992</fpage><lpage>1999</lpage><pub-id pub-id-type="pmid">37352110</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavelaar</surname><given-names>H</given-names></name><etal/></person-group><article-title>Development of a EUCAST disk diffusion method for the susceptibility testing of rapidly growing anaerobic bacteria using Fastidious Anaerobe Agar (FAA): a development study using Bacteroides species</article-title><source>Clin Microbiol Infect</source><year>2021</year><volume>27</volume><issue>11</issue><elocation-id>1695 e1-1695 e6</elocation-id><pub-id pub-id-type="pmid">33813129</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matuschek</surname><given-names>E</given-names></name><etal/></person-group><article-title>The European committee on antimicrobial susceptibility testing disc diffusion susceptibility testing method for frequently isolated anaerobic bacteria</article-title><source>Clin Microbiol Infect</source><year>2023</year><volume>29</volume><issue>6</issue><elocation-id>795 e1-795 e7</elocation-id><pub-id pub-id-type="pmid">36746258</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olaitan</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><elocation-id>4130</elocation-id><pub-id pub-id-type="pmcid">PMC10338468</pub-id><pub-id pub-id-type="pmid">37438331</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-39429-x</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile</article-title><source>Gastroenterology</source><year>2021</year><volume>160</volume><issue>3</issue><fpage>941</fpage><lpage>945</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC7878333</pub-id><pub-id pub-id-type="pmid">33197449</pub-id><pub-id pub-id-type="doi">10.1053/j.gastro.2020.10.046</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darkoh</surname><given-names>C</given-names></name><etal/></person-group><article-title>Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin</article-title><source>Clin Infect Dis</source><year>2022</year><volume>74</volume><issue>1</issue><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="pmcid">PMC8752249</pub-id><pub-id pub-id-type="pmid">35016207</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciaa912</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutgring</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Are Vancomycin Non-Susceptible Clostridioides difficile Strains Emerging?</article-title><source>Clin Infect Dis</source><year>2022</year><volume>75</volume><issue>9</issue><fpage>1677</fpage><lpage>1678</lpage><pub-id pub-id-type="pmcid">PMC10150788</pub-id><pub-id pub-id-type="pmid">35818797</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciac375</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="web"><collab>EUCAST</collab><source>Clinical breakpoints</source><year>2024</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.eucast.org/clinical_breakpoints/">http://www.eucast.org/clinical_breakpoints/</ext-link></comment></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Comparison of MIC values for Leeds (A) and Leiden (B).</title><p>Individual datapoints are shown, with the mean indicated with the largest circle. Data is shown for fidaxomicin (FDX, ochre), metronidazole (MTZ, blue) and vancomycin (VAN, green) on three different media: brucella blood agar (BBA), fastidious anaerobe agar (FAA-HB) and Wilkins-Chalgren (WC). For details see <xref ref-type="sec" rid="S6">Methods</xref>.</p></caption><graphic xlink:href="EMS200047-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Inter-site reproducibility of antimicrobial susceptibility testing.</title><p><bold>A</bold>. Ratios of MIC values obtained at the two sites were calculated for each isolate. Individual datapoints are shown, with the mean indicated with the largest circle. Data is shown for fidaxomicin (FDX, ochre), metronidazole (MTZ, blue) and vancomycin (VAN, green) on three different media: brucella blood agar (BBA), fastidious anaerobe agar (FAA-HB) and Wilkins-Chalgren (WC). <bold>B</bold>. The number of isolates with MIC≥1 mg/L (FDX) or MIC≥4 mg/L (MTZ and VAN) under one or more condition were compared. A value of reflects indicates that 1 isolate met this criterium on one medium. For details see <xref ref-type="sec" rid="S6">Methods</xref>.</p></caption><graphic xlink:href="EMS200047-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>MIC distributions.</title><p>Aggregated data for MICs determined by FAA-HB agar dilution method across both sites for fidaxomicin (orange) metronidazole (blue) and vancomycin (green).</p></caption><graphic xlink:href="EMS200047-f003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Expected MIC ranges for control strains.</title></caption><table frame="box" rules="all"><thead><tr style="background-color:#000000"><th align="left" valign="top"/><th align="left" valign="top">Metronidazole (mg/L)</th><th align="left" valign="top">Vancomycin (mg/L)</th><th align="left" valign="top">Fidaxomicin (mg/L)</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>B. fragilis</italic> ATCC 25285</td><td align="left" valign="top">0.025-1</td><td align="left" valign="top">N/A</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top"><italic>C. difficile</italic> E4</td><td align="left" valign="top">4-16</td><td align="left" valign="top">0.5-4</td><td align="left" valign="top">0.03-0.125</td></tr><tr><td align="left" valign="top"><italic>C difficile</italic> ATCC 700057</td><td align="left" valign="top">0.125 - 0.5</td><td align="left" valign="top">0.5-4</td><td align="left" valign="top">0.03-0.125</td></tr><tr><td align="left" valign="top"><italic>E. faecalis</italic> ATCC 29212</td><td align="left" valign="top">&gt;32</td><td align="left" valign="top">2-8</td><td align="left" valign="top">2-8</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Aggregated MIC values.</title><p>MIC values for individual isolates were aggregated to the concentration that inhibits the growth of &gt;50% of all isolates (MIC50) or &gt;90% of all isolates (MIC90). Data is shown for fidaxomicin (FDX), metronidazole (MTZ) and vancomycin (VAN) on three different media: brucella blood agar (BBA), fastidious anaerobe agar (FAA-HB) and Wilkins-Chalgren (WC). For details see <xref ref-type="sec" rid="S6">Methods</xref>.</p></caption><table frame="box" rules="groups"><thead><tr style="background-color:#000000"><th align="left" valign="bottom">Site</th><th align="left" valign="bottom">Antimicrobial</th><th align="left" valign="bottom">Medium</th><th align="left" valign="top">MIC<sub>50</sub> (mg/L)</th><th align="left" valign="top">MIC<sub>90</sub> (mg/L)</th><th align="left" valign="top">MIC range (mg/L)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="9">Leeds</td><td align="left" valign="top" rowspan="3">FDX</td><td align="left" valign="top">BBA</td><td align="right" valign="top">0.125</td><td align="right" valign="top">0.5</td><td align="right" valign="top">0.002-32</td></tr><tr><td align="left" valign="top">FAA-HB</td><td align="right" valign="top">0.25</td><td align="right" valign="top">0.5</td><td align="right" valign="top">0.004-32</td></tr><tr><td align="left" valign="top">WC</td><td align="right" valign="top">0.06</td><td align="right" valign="top">0.125</td><td align="right" valign="top">0.002-16</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2" rowspan="3">MTZ</td><td align="left" valign="top" style="background-color:#F2F2F2">BBA</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">0.5</td><td align="right" valign="top" style="background-color:#F2F2F2">0.03-2</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2">FAA-HB</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">1</td><td align="right" valign="top" style="background-color:#F2F2F2">0.03-8</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2">WC</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">2</td><td align="right" valign="top" style="background-color:#F2F2F2">0.03-8</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9" rowspan="3">VAN</td><td align="left" valign="top" style="background-color:#D9D9D9">BBA</td><td align="right" valign="top" style="background-color:#D9D9D9">0.5</td><td align="right" valign="top" style="background-color:#D9D9D9">1</td><td align="right" valign="top" style="background-color:#D9D9D9">0.06-4</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9">FAA-HB</td><td align="right" valign="top" style="background-color:#D9D9D9">0.5</td><td align="right" valign="top" style="background-color:#D9D9D9">1</td><td align="right" valign="top" style="background-color:#D9D9D9">0.03-8</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9">WC</td><td align="right" valign="top" style="background-color:#D9D9D9">0.5</td><td align="right" valign="top" style="background-color:#D9D9D9">1</td><td align="right" valign="top" style="background-color:#D9D9D9">0.06-4</td></tr><tr style="border-top: solid thin"><td align="left" valign="top" rowspan="9">Leiden</td><td align="left" valign="top" rowspan="3">FDX</td><td align="left" valign="top">BBA</td><td align="right" valign="top">0.25</td><td align="right" valign="top">0.5</td><td align="right" valign="top">0.03-32</td></tr><tr><td align="left" valign="top">FAA-HB</td><td align="right" valign="top">0.25</td><td align="right" valign="top">0.5</td><td align="right" valign="top">0.03-32</td></tr><tr><td align="left" valign="top">WC</td><td align="right" valign="top">0.125</td><td align="right" valign="top">0.25</td><td align="right" valign="top">0.004-16</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2" rowspan="3">MTZ</td><td align="left" valign="top" style="background-color:#F2F2F2">BBA</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">1</td><td align="right" valign="top" style="background-color:#F2F2F2">0.03-8</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2">FAA-HB</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">2</td><td align="right" valign="top" style="background-color:#F2F2F2">0.06-8</td></tr><tr><td align="left" valign="top" style="background-color:#F2F2F2">WC</td><td align="right" valign="top" style="background-color:#F2F2F2">0.25</td><td align="right" valign="top" style="background-color:#F2F2F2">2</td><td align="right" valign="top" style="background-color:#F2F2F2">0.03-8</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9" rowspan="3">VAN</td><td align="left" valign="top" style="background-color:#D9D9D9">BBA</td><td align="right" valign="top" style="background-color:#D9D9D9">2</td><td align="right" valign="top" style="background-color:#D9D9D9">2</td><td align="right" valign="top" style="background-color:#D9D9D9">0.5-4</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9">FAA-HB</td><td align="right" valign="top" style="background-color:#D9D9D9">1</td><td align="right" valign="top" style="background-color:#D9D9D9">2</td><td align="right" valign="top" style="background-color:#D9D9D9">0.5-8</td></tr><tr><td align="left" valign="top" style="background-color:#D9D9D9">WC</td><td align="right" valign="top" style="background-color:#D9D9D9">1</td><td align="right" valign="top" style="background-color:#D9D9D9">2</td><td align="right" valign="top" style="background-color:#D9D9D9">0.125-4</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><title>Recommended <italic>C. difficile</italic> strains for antimicrobial susceptibility testing of <italic>C. difficile</italic> on FAA-HB medium with MIC values as determined in this study.</title></caption><table frame="box" rules="all"><thead><tr style="background-color:#000000"><th align="left" valign="top">Isolate</th><th align="left" valign="top">NCTC accession</th><th align="left" valign="top">Fidaxomicin MIC (mg/L)</th><th align="left" valign="top">Metronidazole MIC (mg/L)</th><th align="left" valign="top">Vancomycin MIC (mg/L)</th><th align="left" valign="top">Description</th><th align="left" valign="top">Reference</th></tr></thead><tbody><tr style="background-color:#CCCCCC"><td align="left" valign="top"><bold>15-7365627</bold></td><td align="left" valign="top">NCTC 15114</td><td align="left" valign="top">0.25</td><td align="left" valign="top">4</td><td align="left" valign="top">0.5-2</td><td align="left" valign="top">RT016.Medium dependent resistance<xref ref-type="table-fn" rid="TFN1">#</xref>.</td><td align="left" valign="top">This study</td></tr><tr><td align="left" valign="top"><bold>E4</bold></td><td align="left" valign="top">NCTC 15085</td><td align="left" valign="top">0.125</td><td align="left" valign="top">4-16</td><td align="left" valign="top">0.5-1</td><td align="left" valign="top">RT010</td><td align="left" valign="top">[30]</td></tr><tr style="background-color:#CCCCCC"><td align="left" valign="top"><bold>L_16.7570132</bold></td><td align="left" valign="top">NCTC 15086</td><td align="left" valign="top">32</td><td align="left" valign="top">0.25</td><td align="left" valign="top">1.0</td><td align="left" valign="top">RT344</td><td align="left" valign="top">[21], this study</td></tr><tr><td align="left" valign="top"><bold>L_13.7933412</bold></td><td align="left" valign="top">NCTC 15087</td><td align="left" valign="top">0.125-0.25</td><td align="left" valign="top">0.125-0.25</td><td align="left" valign="top">8</td><td align="left" valign="top">RT356</td><td align="left" valign="top">This study</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>#</label><p id="P44">For medium-independent metronidazole resistance, the pCD-METRO containing strain IB136 [<xref ref-type="bibr" rid="R12">12</xref>] (NCTC 14835) can be used, that has a MIC of 8-16 mg/L.</p></fn></table-wrap-foot></table-wrap></floats-group></article>